Indication

Refractory/Relapsed Acute Myeloid Leukemia

1 clinical trial

1 product

Clinical trial

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia：a Single-center, Open-label, Non-randomised, Single-arm Phase Ⅰ Clinical Trial

Status: Not yet recruiting, Estimated PCD: 2026-06-15

Product